ATXN3L: A Key Protein Regulator of Neural Response To Environmental Changes

Target Name: ATXN3L

NCBI ID: G92552

ATXN3L

ATXN3L: A Key Protein Regulator of Neural Response To Environmental Changes

ATXN3L (Machado-Joseph Disease Protein 1-Like) is a protein that is expressed in the brain and is known to be a key regulator of the neural response to changes in the environment. The protein is named after Dr. Ataxia Nusslock, a researcher who first identified its role in the brain.

ATXN3L is a member of the protein family known as the Machado-Joseph disease (MJD) protein family. This family of proteins is known for its role in the development and progression of a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

ATXN3L is expressed in the brain and is involved in the regulation of a variety of cellular processes, including the development and maintenance of the brain's barrier, the production of new neurons, and the response to neurotransmitters. It is also involved in the regulation of the immune system and has been shown to play a role in the development of multiple sclerosis.

In recent years, researchers have been interested in using ATXN3L as a drug target or biomarker for a variety of neurodegenerative diseases. This is because the protein is well- conserved and has been shown to be involved in the development and progression of a variety of neurodegenerative diseases.

One potential approach to using ATXN3L as a drug target is to target the protein using small molecules or antibodies that can interact with it. This approach is being explored as a potential treatment for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

Another potential approach to using ATXN3L as a biomarker is to use it as a diagnostic tool for neurodegenerative diseases. This is being done by using the protein to develop diagnostic tests that can be used to diagnose neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Research has also been done to see if ATXN3L can be used as a potential biomarker for other neurodegenerative diseases, such as ALS and PD. Initial studies have shown that the protein is expressed in the brains of individuals with these diseases and that it is involved in the development and progression of these diseases.

Overall, ATXN3L is a protein that is well- conserved and has been shown to be involved in the development and progression of a variety of neurodegenerative diseases. As a result, it is an attractive target for drug development and research into the underlying causes of these diseases.

Protein Name: Ataxin 3 Like

Functions: Deubiquitinating enzyme that cleaves both 'Lys-48'-linked and 'Lys-63'-linked poly-ubiquitin chains (in vitro)

The "ATXN3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATXN3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets